Arming tumor-reactive T cells with costimulator B7-1 enhances therapeutic efficacy of the T cells

Cancer Research

Volumn 66, Issue 13, 2006, Pages 6793-6799

  Zheng, Guoxing ^a   Liu, Shanrong ^a,b   Wang, Peijie ^c   Xu, Ying ^a   Chen, Aoshuang ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; OVALBUMIN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; IMMUNOGENICITY; IMMUNOSTIMULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; TUMOR CELL; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD80; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PROTEIN ENGINEERING;

EID: 33746123933     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0435     Document Type: Article

References (35)

1. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003;3:666-75.
2. Yannelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 2004;23:97-113.
3. Melero I, Bach N, Chen L. Costimulation, tolerance, and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens. Life Sci 1997;60:2035-41.
4. Spiotto MT, Fu YX, Schreiber H. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr Opin Immunol 2003;15:725-30.
5. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
6. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-53.
7. Gimmi CD, Freeman GJ, Gribben JG, Gray G, Nadler LM. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A 1993;90:6586-90.
8. Bai XF, Bender J, Liu J, et al. Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol 2001;167:3936-43.
9. Allison J, Stephens LA, Kay TW, et al. The threshold for autoimmune T cell killing is influenced by B7-1. Eur J Immunol 1998;28:949-60.
10. Guilloux Y, Bai XF, Liu X, Zheng P, Liu Y. Optimal induction of effector but not memory antitumor cytotoxic T lymphocytes involves direct antigen presentation by the tumor cells. Cancer Res 2001;61:1107-12.
11. George TC, Bilsborough J, Viney JL, Norment AM. High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. Eur J Immunol 2003;33:502-11.
12. high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53.
13. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-96.
14. Weintraub JP, Cohen PL. Ectopic expression of B7-1 (CD80) on T lymphocytes in autoimmune lpr and gld mice. Clin Immunol 1999;91:302-9.
15. Kinoshita K, Tesch G, Schwarting A, Maron R, Sharpe AH, Kelley VR. Costimulation by B7-1 and B7-2 is required for autoimmune disease in MRL-Faslpr mice. J Immunol 2000;164:6046-56.
16. Wagner DH, Jr., Vaitaitis G, Sanderson R, Poulin M, Dobbs C, Haskins K. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc Natl Acad Sci U S A 2002;99:3782-7.
17. Wang J, Lo JC, Foster A, et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest 2001;108:1771-80.
18. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004;4:401-11.
19. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
20. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994;76:17-27.
21. Chen A, Zheng G, Tykocinski ML. Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method. J Immunol 2000;164:705-11.
22. Zheng G, Chen A, Sterner RE, et al. Induction of antitumor immunity via intratumoral tetra-costimulator protein transfer. Cancer Res 2001;61:8127-34.
23. Winn HJ. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J Immunol 1961;86:228-39.
24. Parviz M, Chin CS, Graham LJ, et al. Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother 2003;52:739-50.
25. Chen A, Zheng G, Tykocinski ML. Quantitative interplay between activating and pro-apoptotic signals dictates T cell responses. Cell Immunol 2003;221:128-37.
26. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988;54:777-85.
27. Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res 2000;2:331-4.
28. Tykocinski ML, Shu HK, Ayers DJ, et al. Glycolipid reanchoring of T-lymphocyte surface antigen CD8 using the 3′ end sequence of decay-accelerating factor's mRNA. Proc Natl Acad Sci U S A 1988;85:3555-9.
29. Huang JH, Getty RR, Chisari FV, Fowler P, Greenspan NS, Tykocinski ML. Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis. Immunity 1994;1:607-13.
30. McHugh RS, Ahmed SN, Wang YC, Sell KW, Selvaraj P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci U S A 1995;92:8059-63.
31. Tykocinski ML, Chen A, Huang JH, Weber MC, Zheng G. New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints. Immunol Res 2003;27:565-74.
32. Cimino AM, Palaniswami P, Kim AC, Selvaraj P. Cancer vaccine development: protein transfer of membrane-anchored cytokines and immunostimulatory molecules. Immunol Res 2004;29:231-40.
33. Yu P, Lee Y, Liu W, et al. Priming of naïve T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004;5:141-9.
34. Liu Y, Janeway CA, Jr. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci U S A 1992;89:3845-9.
35. Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A 2004;101:10398-403.